Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
Flagship Pioneering has unveiled Abiologics, a company developing a new class of supranatural and programmable medicines called Synteins™. These are computationally-generated and synthesized with novel building blocks, aiming to overcome limitations of traditional biologics. The Abiologics platform uses generative AI and high-throughput chemical protein synthesis to create Synteins with extraordinary properties.
Flagship has initially committed $50 million to advance the platform and develop a pipeline of medicines, focusing on oncology and immunology. Synteins can be programmed to interact with virtually any therapeutic target while evading the body's natural defenses, offering advantages such as less frequent dosing, oral delivery, and access to previously unreachable parts of the body.
Flagship Pioneering ha presentato Abiologics, un'azienda che sta sviluppando una nuova classe di medicine soprannaturali e programmabili chiamate Synteins™. Queste sono generate computazionalmente e sintetizzate con nuovi elementi costitutivi, con l'obiettivo di superare i limiti dei biologici tradizionali. La piattaforma Abiologics utilizza AI generativa e sintesi chimica proteica ad alta capacità per creare Synteins con proprietà straordinarie.
Flagship ha inizialmente impegnato 50 milioni di dollari per far progredire la piattaforma e sviluppare una pipeline di medicine, concentrandosi su oncologia e immunologia. I Synteins possono essere programmati per interagire con praticamente qualsiasi obiettivo terapeutico, evadendo le difese naturali del corpo, offrendo vantaggi come dosaggi meno frequenti, somministrazione orale e accesso a parti del corpo precedentemente inaccessibili.
Flagship Pioneering ha presentado Abiologics, una empresa que desarrolla una nueva clase de medicamentos supranaturales y programables llamados Synteins™. Estos son generados computacionalmente y sintetizados con nuevos bloques de construcción, con el objetivo de superar las limitaciones de los biológicos tradicionales. La plataforma Abiologics utiliza IA generativa y síntesis química de proteínas a gran escala para crear Synteins con propiedades extraordinarias.
Flagship ha comprometido inicialmente 50 millones de dólares para avanzar en la plataforma y desarrollar un conjunto de medicamentos, enfocándose en oncología e inmunología. Los Synteins pueden ser programados para interactuar con prácticamente cualquier objetivo terapéutico, evadiendo las defensas naturales del cuerpo, ofreciendo ventajas como dosificación menos frecuente, administración oral y acceso a partes del cuerpo que antes eran inalcanzables.
Flagship Pioneering은 새로운 종류의 초자연적이고 프로그래밍 가능한 의약품인 Synteins™을 개발하는 회사인 Abiologics를 공개했습니다. 이들은 컴퓨터로 생성되고 새로운 구축 요소로 합성되며, 전통적인 생물학적 제약의 한계를 극복하는 것을 목표로 합니다. Abiologics 플랫폼은 생성 AI와 고속 화학 단백질 합성을 사용하여 특별한 특성을 가진 Synteins를 만듭니다.
Flagship은 처음에 5000만 달러를 투자하여 플랫폼을 발전시키고 종양학과 면역학에 중점을 둔 의약품 파이프라인을 개발하기로 약속했습니다. Synteins는 거의 모든 치료 타겟과 상호작용하도록 프로그래밍할 수 있으며, 신체의 자연 방어 체계를 회피할 수 있어 더 적은 빈도의 투약, 경구 투여, 그리고 이전에는 접근할 수 없었던 신체 부위에 접근할 수 있는 장점을 제공합니다.
Flagship Pioneering a dévoilé Abiologics, une entreprise développant une nouvelle classe de médicaments surnaturels et programmables appelés Synteins™. Ceux-ci sont générés par ordinateur et synthétisés avec de nouveaux blocs de construction, visant à surmonter les limites des biologiques traditionnels. La plateforme Abiologics utilise IA générative et la synthèse chimique de protéines à haut débit pour créer des Synteins aux propriétés extraordinaires.
Flagship s'est initialement engagé à investir 50 millions de dollars pour faire avancer la plateforme et développer un pipeline de médicaments, en se concentrant sur l'oncologie et l'immunologie. Les Synteins peuvent être programmés pour interagir avec pratiquement n'importe quelle cible thérapeutique tout en évitant les défenses naturelles du corps, offrant des avantages tels qu'un dosage moins fréquent, une administration orale et un accès à des parties du corps auparavant inaccessibles.
Flagship Pioneering hat Abiologics eingeführt, ein Unternehmen, das eine neue Klasse von übernatürlichen und programmierbaren Medikamenten namens Synteins™ entwickelt. Diese werden computergestützt generiert und mit neuartigen Bausteinen synthetisiert, um die Einschränkungen traditioneller Biologika zu überwinden. Die Abiologics-Plattform nutzt generative KI und Hochdurchsatz-Chemie-Protein-Synthese, um Synteins mit außergewöhnlichen Eigenschaften zu kreieren.
Flagship hat zunächst 50 Millionen Dollar für die Weiterentwicklung der Plattform und den Aufbau einer Pipeline von Medikamenten bereitgestellt, wobei der Fokus auf Onkologie und Immunologie liegt. Synteins können programmiert werden, um mit praktisch jedem therapeutischen Ziel zu interagieren und gleichzeitig die natürlichen Abwehrkräfte des Körpers zu umgehen, was Vorteile wie weniger häufige Dosierung, orale Verabreichung und den Zugang zu zuvor unerreichbaren Körperteilen bietet.
- Initial commitment of $50 million from Flagship Pioneering
- Development of a new class of supranatural and programmable medicines (Synteins™)
- Potential for less frequent dosing, oral delivery, and access to previously unreachable parts of the body
- Focus on oncology and immunology indications
- Successful generation of Synteins made entirely of D-amino acids binding to therapeutically relevant targets
- None.
Flagship Pioneering's $50 million initial commitment to Abiologics signals strong financial backing and confidence in the new platform's potential. This significant investment aims to develop revolutionary biologics that could address unmet needs in oncology and immunology, areas with consistently high market demand. For retail investors, the financial implication is twofold: the potential for significant returns if Abiologics' Synteins achieve clinical and commercial success and the short-term impact of high R&D costs. It's important to monitor how this substantial upfront investment translates into tangible results over the next few years.
Furthermore, the innovative nature of Synteins could attract additional funding or partnerships, enhancing Abiologics' financial stability and growth prospects. Investors should keep an eye on any upcoming clinical trials and preliminary data releases, which will be pivotal in reassessing the financial outlook of this venture.
The introduction of Synteins as a novel class of biologics represents a paradigm shift in therapeutic development. Leveraging generative AI and chemical synthesis to create supranatural biologics with artificial building blocks, Abiologics is poised to address critical limitations of current treatments. For retail investors, this innovation broadens the therapeutic landscape, particularly in oncology and immunology, where there is a constant need for more effective and less toxic treatments.
Notably, the use of D-amino acids to evade immune responses is groundbreaking. This could result in fewer side effects, improved patient compliance due to less frequent dosing and the ability to target previously inaccessible tissues. However, the long-term clinical efficacy and safety of these synthetic biologics remain to be seen. Investors should watch for early-stage clinical trial results, as they will provide critical insights into the viability and potential success of Synteins.
The convergence of generative AI and high throughput chemical protein synthesis in the Abiologics platform emphasizes the transformative potential of technology in drug development. This integration allows for the creation of biologics with unprecedented precision and diversity, potentially revolutionizing how we approach treatment for various diseases.
For retail investors, the technological advancements underpinning Abiologics are a significant value add. The use of AI to design Synteins and the automated, scalable nature of the synthesis process could lead to more rapid and cost-effective development cycles compared to traditional biologics. This technological edge may give Abiologics a competitive advantage, enabling it to bring novel therapies to market faster. Investors should consider the robustness of the technology platform and any intellectual property protections that could safeguard these innovations from competitors.
The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients
The company emerges after 3 years of platform development and an initial commitment of
"Biologics have transformed medicine in the past forty years, but only a fraction of their potential has been realized because we've been limited by the boundaries of nature," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Abiologics. "With the convergence of advancements in generative artificial intelligence, automated polymer synthesis and chemical functionalization coupled with a vision to develop more powerful medicines with unprecedented diversity, we asked, what if we could design biologics entirely from new building blocks that could overcome the most critical limitations of today's medicines?"
The Abiologics platform is a fully integrated digital and automated wet-lab infrastructure to create supranatural biologics with powerful, desirable pharmacological properties. The platform leverages state-of-the-art generative artificial intelligence (AI) to computationally-design Synteins de novo using a broad set of artificial building blocks, far beyond the 20 naturally occurring amino acids that form the basis of today's biologic medicines. These include biologics built with D-amino acids, chemically identical mirror images of standard amino acids. Once designed, Abiologics chemically synthesizes its digitally-optimized Synteins with pioneering new technologies. As a result, Synteins can be programmed to interact with virtually any therapeutic target while evading the body's natural defenses. By surpassing the limitations of traditional biologics discovery tools, Abiologics is the first to discover, prototype and scale-up polymers composed solely of artificial building blocks, and to date has successfully generated Synteins made entirely of D-amino acids that bind a diversity of therapeutically relevant targets while remaining ultrastable.
"For the first time, we are able to imagine and generate chemically synthesized biologics at scale and with increasing programmability, offering a new class of medicines with transformative potential," said Avak Kahvejian, Ph.D., Co-Founder and CEO of Abiologics and General Partner at Flagship Pioneering. "Creating protein biologics with artificial building blocks rather than naturally occurring amino acids allows Synteins to go unrecognized by the immune system, offering significant advantages compared to today's biologics such as less frequent dosing, oral delivery and the ability to reach parts of the body that were previously impossible to access and treat. With Synteins, Abiologics is poised to bring boundary-breaking medicines to patients across a range of diseases."
In addition to Afeyan and Kahvejian, Abiologics' founding team includes Mike Hamill, Ph.D., Chief Innovation Officer of Abiologics and Senior Principal at Flagship Pioneering, Kala Subramanian, Ph.D., Founding President of Abiologics and Operating Partner at Flagship Pioneering, Jaclyn Dunphy, Ph.D., Senior Director of Strategy and Research Operations at Abiologics, and Alicia Kaestli, Ph.D., Senior Associate at Flagship Pioneering. Bradley Pentelute, Ph.D., Professor of Chemistry at MIT, is an Academic Co-Founder of Abiologics.
About Abiologics
Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021. For more information, visit us at www.abiologics.com and follow us on LinkedIn and X/Twitter.
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
Media Contact:
press@flagshippioneering.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-abiologics-to-pioneer-supranatural-biologics-a-new-biotherapeutic-class-302203247.html
SOURCE Flagship Pioneering
FAQ
What is Abiologics and what are Synteins™?
How much has Flagship Pioneering initially committed to Abiologics?
What are the potential advantages of Synteins™ over traditional biologics?
What therapeutic areas is Abiologics initially focusing on?
